These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 23332170)

  • 21. Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers.
    Umeda T; Ono K; Sakai A; Yamashita M; Mizuguchi M; Klein WL; Yamada M; Mori H; Tomiyama T
    Brain; 2016 May; 139(Pt 5):1568-86. PubMed ID: 27020329
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Locus Coeruleus Ablation Exacerbates Cognitive Deficits, Neuropathology, and Lethality in P301S Tau Transgenic Mice.
    Chalermpalanupap T; Schroeder JP; Rorabaugh JM; Liles LC; Lah JJ; Levey AI; Weinshenker D
    J Neurosci; 2018 Jan; 38(1):74-92. PubMed ID: 29133432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early intervention of tau pathology prevents behavioral changes in the rTg4510 mouse model of tauopathy.
    Wang X; Smith K; Pearson M; Hughes A; Cosden ML; Marcus J; Hess JF; Savage MJ; Rosahl T; Smith SM; Schachter JB; Uslaner JM
    PLoS One; 2018; 13(4):e0195486. PubMed ID: 29624602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models.
    Sankaranarayanan S; Barten DM; Vana L; Devidze N; Yang L; Cadelina G; Hoque N; DeCarr L; Keenan S; Lin A; Cao Y; Snyder B; Zhang B; Nitla M; Hirschfeld G; Barrezueta N; Polson C; Wes P; Rangan VS; Cacace A; Albright CF; Meredith J; Trojanowski JQ; Lee VM; Brunden KR; Ahlijanian M
    PLoS One; 2015; 10(5):e0125614. PubMed ID: 25933020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice.
    Peeraer E; Bottelbergs A; Van Kolen K; Stancu IC; Vasconcelos B; Mahieu M; Duytschaever H; Ver Donck L; Torremans A; Sluydts E; Van Acker N; Kemp JA; Mercken M; Brunden KR; Trojanowski JQ; Dewachter I; Lee VM; Moechars D
    Neurobiol Dis; 2015 Jan; 73():83-95. PubMed ID: 25220759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of the C57BL/6 strain background on tauopathy progression in the rTg4510 mouse model.
    Bailey RM; Howard J; Knight J; Sahara N; Dickson DW; Lewis J
    Mol Neurodegener; 2014 Jan; 9():8. PubMed ID: 24428919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models.
    Lee S; Varvel NH; Konerth ME; Xu G; Cardona AE; Ransohoff RM; Lamb BT
    Am J Pathol; 2010 Nov; 177(5):2549-62. PubMed ID: 20864679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sustained Arginase 1 Expression Modulates Pathological Tau Deposits in a Mouse Model of Tauopathy.
    Hunt JB; Nash KR; Placides D; Moran P; Selenica ML; Abuqalbeen F; Ratnasamy K; Slouha N; Rodriguez-Ospina S; Savlia M; Ranaweera Y; Reid P; Dickey CA; Uricia R; Yang CG; Sandusky LA; Gordon MN; Morgan D; Lee DC
    J Neurosci; 2015 Nov; 35(44):14842-60. PubMed ID: 26538654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Organotypic brain slice cultures of adult transgenic P301S mice--a model for tauopathy studies.
    Mewes A; Franke H; Singer D
    PLoS One; 2012; 7(9):e45017. PubMed ID: 22984603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy.
    Graham DL; Gray AJ; Joyce JA; Yu D; O'Moore J; Carlson GA; Shearman MS; Dellovade TL; Hering H
    Neuropharmacology; 2014 Apr; 79():307-13. PubMed ID: 24326295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's disease.
    Stozicka Z; Zilka N; Novak P; Kovacech B; Bugos O; Novak M
    J Neuroinflammation; 2010 Oct; 7():64. PubMed ID: 20937161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heterozygous CX3CR1 Deficiency in Microglia Restores Neuronal β-Amyloid Clearance Pathways and Slows Progression of Alzheimer's Like-Disease in PS1-APP Mice.
    Hickman SE; Allison EK; Coleman U; Kingery-Gallagher ND; El Khoury J
    Front Immunol; 2019; 10():2780. PubMed ID: 31849963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. THY-Tau22 mouse model accumulates more tauopathy at late stage of the disease in response to microglia deactivation through TREM2 deficiency.
    Vautheny A; Duwat C; Aurégan G; Joséphine C; Hérard AS; Jan C; Mitja J; Gipchtein P; Gaillard MC; Buée L; Blum D; Hantraye P; Bonvento G; Brouillet E; Cambon K; Bemelmans AP
    Neurobiol Dis; 2021 Jul; 155():105398. PubMed ID: 34019997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CREB-activity and nmnat2 transcription are down-regulated prior to neurodegeneration, while NMNAT2 over-expression is neuroprotective, in a mouse model of human tauopathy.
    Ljungberg MC; Ali YO; Zhu J; Wu CS; Oka K; Zhai RG; Lu HC
    Hum Mol Genet; 2012 Jan; 21(2):251-67. PubMed ID: 22027994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The direct role of 5-lipoxygenase on tau pathology, synaptic integrity and cognition in a mouse model of tauopathy.
    Vagnozzi AN; Giannopoulos PF; Praticò D
    Transl Psychiatry; 2017 Dec; 7(12):1288. PubMed ID: 29249809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biologic TNF-α inhibitors reduce microgliosis, neuronal loss, and tau phosphorylation in a transgenic mouse model of tauopathy.
    Ou W; Yang J; Simanauskaite J; Choi M; Castellanos DM; Chang R; Sun J; Jagadeesan N; Parfitt KD; Cribbs DH; Sumbria RK
    J Neuroinflammation; 2021 Dec; 18(1):312. PubMed ID: 34972522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Visual Evoked Potentials as an Early-Stage Biomarker in the rTg4510 Tauopathy Mouse Model.
    Parka A; Volbracht C; Hall B; Bastlund JF; Nedergaard M; Laursen B; Botta P; Sotty F
    J Alzheimers Dis; 2023; 93(1):247-262. PubMed ID: 37005884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy.
    Berger Z; Roder H; Hanna A; Carlson A; Rangachari V; Yue M; Wszolek Z; Ashe K; Knight J; Dickson D; Andorfer C; Rosenberry TL; Lewis J; Hutton M; Janus C
    J Neurosci; 2007 Apr; 27(14):3650-62. PubMed ID: 17409229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Partial reduction of microglia does not affect tau pathology in aged mice.
    Bennett RE; Bryant A; Hu M; Robbins AB; Hopp SC; Hyman BT
    J Neuroinflammation; 2018 Nov; 15(1):311. PubMed ID: 30413160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of tau pathology in tau transgenic models.
    Brion JP; Ando K; Heraud C; Leroy K
    Biochem Soc Trans; 2010 Aug; 38(4):996-1000. PubMed ID: 20658992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.